NASDAQ:NK - NantKwest Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.67
▲ +0.43 (6.89%)
Get New NantKwest Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NantKwest in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.67.

This chart shows the closing price for NK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in NantKwest. This rating has held steady since June 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/8/2020Piper SandlerInitiated CoverageOverweight$18.00High
5/30/2019CitigroupDowngradeNeutral ➝ Sell$1.25 ➝ $1.00High
12/9/2018CitigroupLower Price TargetSell ➝ Neutral$3.00 ➝ $2.00Medium
12/2/2018CitigroupLower Price Target$3.00Low
11/30/2018CitigroupUpgradeSell ➝ Neutral$3.00 ➝ $2.00Medium
11/15/2018Jefferies Financial GroupReiterated RatingHold$3.50Low
10/16/2018CitigroupDowngradeNeutral ➝ SellHigh
8/10/2018CitigroupDowngradeHold$3.00Low
8/9/2018CitigroupUpgradeSell ➝ NeutralHigh
12/11/2017Raymond JamesReiterated RatingHoldMedium
8/14/2017CitigroupSet Price TargetSell$3.00Low
5/15/2017CitigroupDowngradeNeutral ➝ Sell$3.00High
5/8/2017Jefferies Financial GroupSet Price TargetHold$4.00Medium
3/17/2017FBR & Co.Reiterated RatingOutperform ➝ Outperform$22.00 ➝ $9.00Low
1/24/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$6.00N/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

-1.59 (Strong Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/17/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
NantKwest logo
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $6.67
Low: $6.04
High: $6.68

50 Day Range

MA: $28.01
Low: $16.09
High: $38.70

52 Week Range

Now: $6.67
Low: $2.52
High: $45.42

Volume

1,382,442 shs

Average Volume

1,568,129 shs

Market Capitalization

$729.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.61

Frequently Asked Questions

What sell-side analysts currently cover shares of NantKwest?

The following sell-side analysts have issued reports on NantKwest in the last year: Zacks Investment Research.
View the latest analyst ratings for NK.

What is the current price target for NantKwest?

0 Wall Street analysts have set twelve-month price targets for NantKwest in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NantKwest in the next year.
View the latest price targets for NK.

What is the current consensus analyst rating for NantKwest?

NantKwest currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NK.

How do I contact NantKwest's investor relations team?

NantKwest's physical mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is 858-633-0300 and its investor relations email address is [email protected] The official website for NantKwest is www.nantkwest.com.